Anaconda BioMed

What Anaconda BioMed does

Anaconda BioMed S.L. is a Barcelona-based medical device start-up founded in 2015 that develops the ANACONDA Platform, a next-generation neurovascular access and protection system anchored by the ANA5 Funnel Catheter. The flagship product is a sterile, single-use catheter made of a radiopaque nitinol braid formed into a self-expanding funnel and covered with a continuous silicone coating; on deployment it expands up to 5mm to match the arterial wall, providing simultaneous local flow restriction, high-efficiency aspiration, and a large receptacle for clot collection during stent retriever-based mechanical thrombectomy for acute ischemic stroke caused by large vessel occlusion. Co-founded by Dr. Ofir Arad (Managing Director) and Dr. Marc Ribó (Hospital Vall d'Hebron), the company is supported by a Scientific Advisory Board of leading neurointerventionalists (Dr. Tudor Jovin, Dr. Raul G. Nogueira, Prof. Tommy Andersson, Prof. Christophe Cognard).

The company's revenue model is hardware sales of single-use catheter kits to hospital neurointerventional radiology departments and stroke units, with a direct enterprise field sales motion in Europe following CE Mark certification on June 26, 2025, and planned US commercialization contingent on FDA approval via the ongoing 327-patient ATHENA pivotal trial (IDE granted July 2024, first US patient April 2025). It is pre-revenue as of 2025. Approximately €45 million has been raised to date through Series A (€15M, 2017), Series B (€20M led by Asabys Partners, December 2019), EIB venture debt (up to €10M, October 2021), and CDTI/Ysios/Asabys investment (January 2025), alongside EU and US patents granted in 2023. The headcount of 11-50 is split between the Sant Quirze del Vallès headquarters and a US operational base in the San Francisco Bay Area established under new CEO Trent Reutiman (appointed January 2025).

Name

Anaconda BioMed

Legal name

ANACONDA BIOMED S.L.

Website

http://anaconda.bio

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Barcelona-based medical device company developing the ANA5 Funnel Catheter, a self-expanding funnel catheter for mechanical thrombectomy in large vessel occlusion acute ischemic stroke, serving hospital neurointerventional radiology and stroke units in Europe (CE Mark, June 2025) with US entry pending FDA approval.

Ownership category

akta.pro rank

Product category

Neurovascular Medical Devices (Mechanical Thrombectomy)

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Infusion Sets, Catheters & Pump Consumables (HLAHAIAH)

Keywords

• Neurovascular catheters
• Mechanical thrombectomy devices
• Endovascular medical devices
• Ischemic stroke treatment
• Neurointerventional radiology tools

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. ANA5 Funnel Catheter (Hardware Sales): As a medical device company with a physical, single-use catheter product, Anaconda Biomed generates revenue through the sale of its ANA5 Funnel Catheter and related procedural kits to hospital catheterization laboratories and neurointerventional radiology departments. Revenue is a mix of direct hospital procurement in CE Mark territories and anticipated US hospital sales following FDA approval. Pre-revenue as of 2025 with CE Mark obtained in June 2025.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Anaconda BioMed develops and manufactures the ANA5 Funnel Catheter — a sterile, single-use, self-expanding, funnel-based catheter composed of a radiopaque nitinol braid covered by a continuous silicone coating. It is designed for mechanical thrombectomy in acute ischemic stroke due to large vessel occlusion, providing high-efficiency aspiration, controlled local flow restriction, minimized embolic risk, and a larger receptacle for clot collection when used as a conduit with stent retrievers.

Product overview

Anaconda BioMed is a Barcelona-based medical device startup developing the ANACONDA Platform - a next-generation endovascular access and protection technology. The company's flagship product is the ANA5 Funnel Catheter, a self-expanding funnel-based catheter designed for use during mechanical thrombectomy in acute ischemic stroke. The platform is specifically designed for neurointerventions and includes a funnel catheter that provides high-efficiency aspiration, controlled flow arrest, and minimized embolic risk. The ANA5 Funnel Catheter is CE mark approved for commercial distribution in Europe and is currently undergoing the ATHENA pivotal clinical trial in the United States.

Differentiator

Problem solved

Functional benefit

Products and services

• ANA5 Funnel Catheter Sterile, single-use, self-expanding, funnel-based catheter composed of a radiopaque nitinol braid covered by a continuous silicone coating; designed for mechanical thrombectomy in acute ischemic stroke due to large vessel occlusion, providing high-efficiency aspiration, controlled flow arrest, minimized embolic risk, and a larger clot collection receptacle when used as a conduit with stent retrievers in hospital neurointerventional procedures.

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• CIMNE (International Centre for Numerical Methods in Engineering)minorStrategic or Co-development Partner · 4 December 2019Anaconda Biomed was awarded a RETOS COLLABORATION grant in conjunction with CIMNE. This collaboration relates to research and development of the thrombectomy system, leveraging computational engineering methods for device design and testing.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Penumbra: Penumbra is a US-based leader in mechanical thrombectomy with its Penumbra System and RED catheter family for stroke aspiration. Directly competes with Anaconda's ANA5 in the same neurovascular hospital accounts and LVO stroke procedures.
• Rapid Medical: Rapid Medical is an Israel-based neurovascular company developing adjustable stent retrievers (TigerTriever) and access devices for stroke. Direct peer with similar clinical-stage development and target customer base of stroke neurointerventionalists.
• Phenox: Phenox is a Germany-based neurovascular company with pRESET stent retriever and pITA access catheters for stroke thrombectomy. Direct competitor with established European hospital presence similar to Anaconda's target accounts.

Broad incumbents

• Stryker (Neurovascular): Stryker's Neurovascular division (acquired from Concentric Medical and Cerenovus) markets stent retrievers, balloon guide catheters, and access products for stroke thrombectomy. Broad incumbent offering overlapping portfolio to hospitals Anaconda targets.
• Medtronic: Medtronic's Neurovascular portfolio (Solitaire stent retriever, React catheter) competes directly in mechanical thrombectomy. As a broad incumbent, it leverages vast resources and global sales infrastructure across stroke centers.
• Johnson & Johnson (Cerenovus): J&J's Cerenovus division offers the EmboTrap stent retriever and a portfolio of neurovascular devices. Broad incumbent with established KOL relationships and integrated stroke care solutions competing head-to-head with Anaconda.

Emerging players

• Imperative Care: Imperative Care is a US-based emerging player in stroke thrombectomy with its Zoom stroke system and large-bore aspiration catheters. Emerging competitor focused on LVO stroke with overlapping technology philosophy of improving aspiration efficiency.
• Vesalio: Vesalio develops the NeVa stent retriever platform for mechanical thrombectomy, with a focus on first-pass complete recanalization. Emerging player directly addressing the same clinical endpoint Anaconda targets.
• Perflow Medical: Perflow Medical is an Israel-based company developing the Stream dynamic neuro-thromboembolectomy device, a braided nitinol design conceptually similar to Anaconda's funnel catheter approach for stroke treatment.
• Nico Corporation: Nico develops the Nico BrainPath and Nico BrainTab systems for neurovascular access, including ischemic stroke procedures. Emerging peer with overlapping catheter technology and similar neurointerventional hospital customers.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/anaconda_biomed
• LinkedInlinkedin.com/company/anaconda-biomed

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anaconda BioMed